# WEEKLY EPIDEMIOLOGY BULLETIN NATIONAL SURVEILLANCE UNIT, MINISTRY OF HEALTH & WELLNESS, JAMAICA

## Weekly Spotlight

## **Tetanus** (Part 3)

## Surveillance

Simultaneously with an increase in control measures, it is critical that an



e in control measures, it is critical that an epidemiologic surveillance system be established or improved. The most basic form of surveillance can be carried out by review of death records. However, as such records may be incomplete, this activity should only complement more active surveillance and reporting mechanisms. For those areas initially

classified as low-risk for neonatal tetanus, improved surveillance will either confirm that status or provide additional information on disease occurrence that will lead to the area being reclassified as high-risk. For those areas already classified as high-risk, the system allows measurement of the impact of neonatal tetanus control measures.

Health care facilities that report tetanus cases should distinguish between neonatal and non-neonatal tetanus. Reports should categorize these cases separately. It may be possible to conduct sentinel surveillance in selected high-risk areas. A representative from the national EPI should inspect such areas periodically. Based on the origin of neonatal patients in a given region, service areas or hospital catchment areas can be established, as well as those areas of the country that do not report cases ("silent" areas). In an adequately functioning surveillance system the ideal is to have both weekly positive and negative reports, that is, the presence or absence of cases should be reported each week. This is very important in helping to define high-risk areas and improve surveillance.

### Active Case-Finding

An enhanced surveillance system should incorporate active or periodic case-finding of newborns with tetanus, particularly in those areas that have not been consistent in reporting or that have reported zero cases for a long period of time. These active case-findings should preferably be carried out for several diseases, thereby using the opportunity to investigate if there are cases of flaccid paralysis, suspicions of neonatal tetanus, or cases of rash with fever. In order to find cases, community leaders, pediatric associations, churches, hospitals, and clinics should be asked to assist in identifying possible cases. Door-to-door visits might be used in areas where patients are unlikely to seek medical care and when there are rumors of a neonatal death compatible with tetanus.



#### SENTINEL SYNDROMIC SURVEILLANCE

## Sentinel Surveillance in Jamaica



Table showcasing the Timeliness of Weekly Sentinel Surveillance Parish Reports for the Four Most Recent Epidemiological Weeks – 9 to 12 of 2025

Parish health departments submit reports weekly by 3 p.m. on Tuesdays. Reports submitted after 3 p.m. are considered late.

### KEY:

Yellow- late submission on Tuesday Red – late submission after Tuesday A syndromic surveillance system is good for early detection of and response to public health events.

Sentinel surveillance occurs when selected health facilities (sentinel sites) form a network that reports on certain health conditions on a regular basis, for example, weekly. Reporting is mandatory whether or not there are cases to report.

Jamaica's sentinel surveillance system concentrates on visits to sentinel sites for health events and syndromes of national importance which are reported weekly (see pages 2 -4). There are seventy-eight (78) reporting sentinel sites (hospitals and health centres) across Jamaica.

| Epi week | Kingston and Saint<br>Andrew | Saint Thomas | Saint Catherine | Portland | Saint Mary | Saint Ann | Trelawny | Saint James | Hanover | Westmoreland | Saint Elizabeth | Manchester | Clarendon |
|----------|------------------------------|--------------|-----------------|----------|------------|-----------|----------|-------------|---------|--------------|-----------------|------------|-----------|
| 2025     |                              |              |                 |          |            |           |          |             |         |              |                 |            |           |
| 9        | On                           | On           | On              | On       | On         | On        | On       | On          | On      | On           | On              | On         | On        |
|          | Time                         | Time         | Time            | Time     | Time       | Time      | Time     | Time        | Time    | Time         | Time            | Time       | Time      |
| 10       | On                           | On           | On              | On       | On         | On        | On       | On          | On      | On           | On              | On         | On        |
|          | Time                         | Time         | Time            | Time     | Time       | Time      | Time     | Time        | Time    | Time         | Time            | Time       | Time      |
| 11       | On                           | On           | On              | On       | On         | On        | On       | On          | On      | On           | On              | On         | On        |
|          | Time                         | Time         | Time            | Time     | Time       | Time      | Time     | Time        | Time    | Time         | Time            | Time       | Time      |
| 12       | On                           | On           | On              | On       | On         | On        | On       | On          | On      | On           | On              | On         | On        |
|          | Time                         | Time         | Time            | Time     | Time       | Time      | Time     | Time        | Time    | Time         | Time            | Time       | Time      |

## REPORTS FOR SYNDROMIC SURVEILLANCE

## UNDIFFERENTIATED FEVER

Temperature of  $>38^{\circ}C$ /100.4°F (or recent history of fever) with or without an obvious diagnosis or focus of infection.





2 NOTIFICATIONS-All clinical sites

1S-

INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





## April 4, 2025

## FEVER AND NEUROLOGICAL

Temperature of >38°C /100.4°F (or recent history of fever) in a previously healthy person with or without headache and vomiting. The person must also have meningeal irritation, convulsions, altered consciousness, altered sensory manifestations or paralysis (except AFP).



## **FEVER AND** HAEMORRHAGIC

Temperature of >38°C /100.4<sup>o</sup>*F* (or recent history of fever) in a previously healthy person presenting with at least one haemorrhagic (bleeding) manifestation with or without jaundice.



## **FEVER AND JAUNDICE**

Temperature of  $>38^{\circ}C/100.4^{\circ}F$ (or recent history of fever) in a previously healthy person presenting with jaundice.

The epidemic threshold is used to confirm the emergence of an epidemic in order to implement control measures. It is calculated using the mean reported cases per week plus 2 standard deviations.



NOTIFICATIONS-3 All clinical sites







SURVEILLANCE-30 sites. Actively pursued



SENTINEL REPORT- 78 sites. Automatic reporting



ISSN 0799-3927



Weekly visits to Sentinel Sites for Fever and Haemorrhagic 2024 and 2025 vs Weekly Threshold; Jamaica



Fever and Jaundice cases: Jamaica, Weekly Threshold vs Cases 2024 and 2025 7 6 Number of visits 5 4 3 2 1 0 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 Epidemiological Week 2024 2025 Alert Threshold Epidemic Threshold





4 NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





## CLASS ONE NOTIFIABLE EVENTS

## Comments

|                    |                          |                  | _ Confirm             | ed YTD <sup><math>\alpha</math></sup> | AFP Field Guides from  |  |  |
|--------------------|--------------------------|------------------|-----------------------|---------------------------------------|--|--|--|
|                    | CLASS 1 EV               | /ENTS            | CURRENT<br>YEAR 2025  | PREVIOUS<br>YEAR 2024                 | WHO indicate that for an effective surveillance                      |  |  |
|                    | Accidental Po            | isoning          | 11 <sup>β</sup>       | 93 <sup>β</sup>                       | AFP should be 1/100,000  |  |  |
| Ţ                  | Cholera                  |                  | 0                     | 0                                     | population under 15 years  |  |  |
| /NO                | Severe Dengu             | eY               | See Dengue page below | See Dengue page below                 | old (0 to 7) cases annually.   |  |  |
| ATI                | COVID-19 (S              | ARS-CoV-2)       | 42                    | 156                                   | Pertussis-like syndrome and  |  |  |
| ERN                | Hansen's Dise            | ease (Leprosy)   | 0                     | 0                                     | Tetanus are clinically   |  |  |
| LER                | Hepatitis B              |                  | 0                     | 11                                    | confirmed classifications.   |  |  |
| AL /               | Hepatitis C              |                  | 0                     | 4                                     | YDengue Hemorrhagic  |  |  |
| NO                 | HIV/AIDS                 |                  | NA                    | NA                                    | Fever data include Dengue  |  |  |
| IATI               | Malaria (Imp             | orted)           | 0                     | 0                                     | related deaths;  |  |  |
| 2                  | Meningitis               |                  | 4                     | 8                                     | $^{\delta}$ Figures include all deaths                               |  |  |
|                    | Monkeypox                |                  | 0                     | 0                                     | associated with pregnancy  |  |  |
| EXOTIC/<br>UNUSUAL | Plague                   |                  | 0                     | 0                                     |  |  |  |
| X/                 | Meningococca             | al Meningitis    | 0                     | 0                                     | <sup>e</sup> CHIKV IgM positive case                                 |  |  |
| GH                 | Neonatal Teta            | nus              | 0                     | 0                                     | <sup><math>\theta</math></sup> Zika PCR positive cases               |  |  |
| H I<br>DRB<br>DRT  | Typhoid Feve             | r                | 0                     | 0                                     | $^{\beta}$ Updates made to prior                                     |  |  |
| MC                 | Meningitis H/            | Flu              | 0                     | 0                                     |  |  |  |
|                    | AFP/Polio                |                  | 0                     | 0                                     | <sup>a</sup> Figures are cumulative<br>totals for all epidemiologica |  |  |
|                    | Congenital Ru            | ıbella Syndrome  | 0                     | 0                                     | weeks year to date.  |  |  |
|                    | Congenital Sy            | rphilis          | 0                     | 0                                     |  |  |  |
| MES                | Fever and                | Measles          | 0                     | 0                                     |  |  |  |
| RAM                | Rash                     | Rubella          | 0                     | 0                                     |  |  |  |
| 903                | Maternal Dear            | ths <sup>δ</sup> | 14                    | 13                                    |  |  |  |
| L PR               | Ophthalmia N             | eonatorum        | 2                     | 38                                    |  |  |  |
| CIA                | Pertussis-like           | syndrome         | 0                     | 0                                     |  |  |  |
| SPE                | Rheumatic Fe             | ver              | 0                     | 0                                     |  |  |  |
|                    | Tetanus                  |                  | 1                     | 0                                     |  |  |  |
|                    | Tuberculosis             |                  | 0                     | 15                                    |  |  |  |
|                    | Yellow Fever             |                  | 0                     | 0                                     |  |  |  |
|                    | Chikungunya <sup>e</sup> |                  |                       | 0                                     |  |  |  |
|                    | Zika Virus <sup>θ</sup>  |                  | 0                     | 0                                     | NA- Not Available  |  |  |

NOTIFICATIONS-5 All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





## April 4, 2025

#### ISSN 0799-3927

| CASES     | EW 12         | Total                 |  |  |
|-----------|---------------|-----------------------|--|--|
| Confirmed | 6             | 157477                |  |  |
| Females   | 5             | 90732                 |  |  |
| Males     | 1             | 66742                 |  |  |
| Age Range | 3 to 84 years | 1 day to 108<br>years |  |  |

#### \* 3 positive cases had no gender specification

\* PCR or Antigen tests are used to confirm cases

\* Total represents all cases confirmed from 10 Mar 2020 to the current Epi-Week.

## COVID-19 Outcomes

| Outcomes                      | EW 12 | Total  |  |  |
|-------------------------------|-------|--------|--|--|
| ACTIVE<br>*2 weeks*           |       | 13     |  |  |
| DIED – COVID<br>Related       | 0     | 3876   |  |  |
| Died - NON<br>COVID           | 0     | 396    |  |  |
| Died - Under<br>Investigation | 0     | 142    |  |  |
| Recovered and<br>discharged   | 0     | 103226 |  |  |
| Repatriated                   | 0     | 93     |  |  |
| Total                         |       | 157477 |  |  |
| *                             |       |        |  |  |

## **COVID-19 Surveillance Update**



3312 COVID-19 Related Deaths since March 1, 2021 – YTD Vaccination Status among COVID-19 Deaths



\*Vaccination programme March 2021 – YTD

\* Total as at current Epi week

### COVID-19 Parish Distribution and Global Statistics





6 NOTIFICATIONS-All clinical sites

![](_page_5_Picture_18.jpeg)

INVESTIGATION REPORTS- Detailed Follow up for all Class One Events

![](_page_5_Picture_20.jpeg)

HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued

![](_page_5_Picture_22.jpeg)

![](_page_5_Picture_24.jpeg)

![](_page_6_Figure_0.jpeg)

ISSN 0799-3927

## **Dengue Bulletin** March 16, 2024 – March 22, 2025 Epidemiological Week 12 Epidemiological Week 12 Dengue Cases by Year: 2004-2025, Jamaica 10000

![](_page_7_Figure_3.jpeg)

![](_page_7_Figure_4.jpeg)

Reported suspected, probable and confirmed dengue with symptom onset in week 12 of 2025

|  | 2025* |     |  |  |
|--|-------|-----|--|--|
|  | EW 12 | YTD |  |  |
| Total Suspected,<br>Probable & Confirmed<br>Dengue Cases | 1     | 121 |  |  |
| Lab Confirmed Dengue<br>cases                            | 0     | 0   |  |  |
| CONFIRMED<br>Dengue Related Deaths                       | 0     | 0   |  |  |

### **Points to note:**

- **Dengue deaths are reported** based on date of death.
- \*Figure as at, April 4, 2025
- **Only PCR positive dengue cases** 0 are reported as confirmed.
- IgM positive cases are classified as presumed dengue.

Symptoms of Dengue fever

![](_page_7_Figure_13.jpeg)

Suspected, probable and confirmed dengue cases for 2023-2025 versus monthly mean, alert and epidemic threshold (2007-2022)

![](_page_7_Figure_15.jpeg)

NOTIFICATIONS-8 All clinical sites

![](_page_7_Picture_17.jpeg)

**INVESTIGATION REPORTS-** Detailed Follow up for all Class One Events

![](_page_7_Picture_19.jpeg)

HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued

![](_page_7_Picture_21.jpeg)

![](_page_7_Picture_23.jpeg)

![](_page_7_Picture_24.jpeg)

# **RESEARCH PAPER**

## Abstract

## NHRC-23-009

# Combined supplementation of S-nitrosoglutathione and glutathione improves glycaemic control in type 2 diabetic rats

Wright, A<sup>1</sup>, Bryan, S.<sup>1</sup>

<sup>1</sup>The University of the West Indies, Mona, Jamaica

**Objectives:** To investigate the effect of the combined supplementation of S-nitrosoglutathione and glutathione on blood glucose concentration in type 2 diabetic rats.

**Methods:** A type 2 diabetic animal model was developed over 4 weeks using 10% fructose solution and lowdose streptozotocin (40 mg/kg BW). Thirty Sprague-Dawley rats were separated equally into five treatment groups, namely, normal control (NC), diabetic control (DC), S-nitrosoglutathione (GSNO), glutathione (GSH) and S-nitrosoglutathione combined with glutathione (GSNO + GSH). The compounds were administered orally (once daily) for 4 weeks, and weekly non-fasting blood glucose concentration was obtained throughout the study. Plasma insulin concentration, in addition to food and fluid intake were also determined at the end of treatment. Data was collected and statistical analysis was done using One-way ANOVA with Tukey posthoc test and a p-value < 0.05 was considered statistically significant.

**Results:** A successful non-genetic animal model of type 2 diabetes was developed. There was a notable reduction in the non-fasting blood glucose concentration following supplementation with GSH only which was even more pronounced with GSNO + GSH treatment (p < 0.05) over the 4 weeks. A concomitant marked increase in insulin concentration for both treatment groups was observed (p < 0.05). The significant decrease in the non-fasting blood glucose concentration was accompanied by a decrease in food and fluid intake for both groups.

**Conclusion:** Combined supplementation of S-nitrosoglutathione and glutathione improved glycaemic control possibly through an insulin-dependent mechanism and decreased symptoms of polyphagia and polydipsia in type 2 diabetic rats. This combined supplementation could potentially be a new treatment strategy for managing type 2 diabetes mellitus.

![](_page_8_Picture_12.jpeg)

The Ministry of Health and Wellness 15 Knutsford Boulevard, Kingston 5, Jamaica Tele: (876) 633-7924 Email: surveillance@moh.gov.jm

9 NOTIFICATIONS-All clinical sites

![](_page_8_Picture_15.jpeg)

INVESTIGATION REPORTS- Detailed Follow up for all Class One Events

![](_page_8_Picture_17.jpeg)

HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued

![](_page_8_Picture_19.jpeg)

![](_page_8_Picture_21.jpeg)